You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm anticipates that in 2019 it will begin clinical trials for a comprehensive metabolic panel for use on its point-of-care platform.
The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.
The firm said the funding will support development of its lupus detection tools, and its acquisition of LupusCorner will support development of a lupus management platform.
The firm said that the funding could boost the presence of its cardiovascular test already on the market in Europe and support the development of others.
The company raised $3.2 million in seed financing, which will go toward development of its platform and deployment of its flagship technology called VIPER.
The funding will be directed at conducting clinical trials for its technology based on activity sensors to detect human diseases and monitor drug responses.
The firm said that it will use the proceeds to roll out a fully automated point-of-care platform that enables use of a broad panel of acute blood biomarkers.
The firm said that its funding will support the launch of targeted breath biopsy kits and enable further investment in its technology platform.
The financing will go toward driving adoption of the company's technology, which can distinguish bacterial infections from viral ones, and other purposes.